Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Telix Pharmaceuticals Ltd. ( (AU:TLX) ) just unveiled an announcement.
Telix Pharmaceuticals Ltd. announced its financial results for the fiscal year ending December 31, 2024, showcasing significant growth with a 56% increase in revenue, reaching AUD 783,207,000, and an 858% surge in profit after tax to AUD 49,919,000. This strong financial performance highlights Telix’s successful market positioning and operational efficiency, although no dividends were declared for the year.
More about Telix Pharmaceuticals Ltd.
Telix Pharmaceuticals Ltd. operates in the biotechnology industry, focusing on developing diagnostic and therapeutic products based on molecularly targeted radiation. The company primarily targets the oncology market, providing innovative solutions for cancer diagnosis and treatment.
YTD Price Performance: 22.55%
Average Trading Volume: 4,376
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $5.81B
See more data about TLX stock on TipRanks’ Stock Analysis page.
